A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Completed
PharmaMar
Phase 2
This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2,
given as a 3 hours intravenous infusion every 2 weeks, in patients with relapsed or
refractory multiple myeloma (MM).
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
Terminated
PharmaMar
Phase 1/Phase 2
This is a Phase I/II study to determine the safety, tolerability and to identify the MTD and
DLT of Plitidepsin in combination with a fixed dose of Cytarabine in patients with
relapsed/refractory leukemia and to determine the response rate of the combination of
Plitidepsin with Cytarabine in patients with relapsed/refractory AML treated at the MTD.
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
Terminated
PharmaMar
Phase 2
This is a study to test the safety and efficacy of an investigational chemotherapy agent in
patients with advanced prostate cancer. Subjects who meet all entry criteria and have signed
the informed consent will be enrolled in the study. Participants will be required to attend
regular clinic visits to receive study medication and have their status monitored. A detailed
explanation can be provided by the investigator conducting the study.
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Completed
PharmaMar
Phase 1
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in
Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas
to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in
combination with sorafenib or gemcitabine in patients with advanced solid tumors or
lymphomas.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
